Lupuzor
Immupharma and Avion sign agreement for lupus drug Lupuzor
November 29, 2019Medical Communications Diseases, Lupus, Lupuzor, avion
Immupharma has signed a development agreement with Avion Pharmaceuticals to acquire the licensing rights for Lupuzor, a peptide therapeutic and …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
